Private Wealth Partners LLC Sells 686 Shares of Zoetis Inc. (NYSE:ZTS)

Private Wealth Partners LLC reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,274 shares of the company’s stock after selling 686 shares during the quarter. Zoetis comprises about 1.0% of Private Wealth Partners LLC’s portfolio, making the stock its 27th biggest position. Private Wealth Partners LLC’s holdings in Zoetis were worth $12,427,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of ZTS. Private Advisor Group LLC boosted its holdings in Zoetis by 2.3% in the fourth quarter. Private Advisor Group LLC now owns 29,149 shares of the company’s stock valued at $4,749,000 after acquiring an additional 654 shares during the last quarter. Bryn Mawr Capital Management LLC boosted its stake in shares of Zoetis by 25.0% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 20,902 shares of the company’s stock valued at $3,406,000 after purchasing an additional 4,178 shares during the last quarter. Alberta Investment Management Corp grew its position in shares of Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after buying an additional 28,700 shares during the period. Legacy Solutions LLC bought a new stake in shares of Zoetis during the fourth quarter worth approximately $209,000. Finally, Bank of Jackson Hole Trust acquired a new position in Zoetis in the fourth quarter valued at approximately $641,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $156.92 on Thursday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company’s 50 day moving average price is $167.29 and its two-hundred day moving average price is $178.29. The company has a market capitalization of $70.27 billion, a P/E ratio of 28.69, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, analysts expect that Zoetis Inc. will post 6.06 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. Zoetis’s payout ratio is presently 36.56%.

Analysts Set New Price Targets

ZTS has been the subject of a number of analyst reports. Barclays lifted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Morgan Stanley dropped their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Piper Sandler decreased their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average target price of $214.90.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.